A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer
Clinical trial NCT02657551 · COMPLETED
Trial details
- NCT number
- NCT02657551
- Sponsor
- Dana-Farber Cancer Institute
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-01-01
- Primary completion
- 2023-08-07
- Enrollment
- 17
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.